Published in Br J Dermatol on November 01, 1999
Do diagnostic delays in cancer matter? Br J Cancer (2009) 2.26
Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20
Neglected Basal cell carcinomas in the 21st century. J Skin Cancer (2010) 1.25
Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study. BMC Fam Pract (2010) 1.00
Dermoscopy as a technique for the early identification of foot melanoma. J Foot Ankle Res (2009) 0.97
Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin). J Invest Dermatol (2005) 0.89
Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care. BMC Dermatol (2013) 0.87
Why are there delays in patients presenting with melanoma? Br J Dermatol (1999) 0.85
Denying the Obvious: Four Extreme Cases of Neglected Tumors. Plast Reconstr Surg Glob Open (2015) 0.75
Delay in cutaneous melanoma diagnosis: Sequence analyses from suspicion to diagnosis in 211 patients. Medicine (Baltimore) (2016) 0.75
Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol (2001) 2.29
Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23
Arterial embolization caused by injection of hyaluronic acid (Restylane). Br J Dermatol (2002) 2.03
[Activity pattern of enzymes of the energy producing metabolism in the normal human epidermis and in psoriasis vulgaris. II]. Arch Klin Exp Dermatol (1966) 1.95
Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer (2009) 1.93
Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol (1990) 1.80
Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol (2002) 1.71
Problems in defining cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. J Clin Epidemiol (1997) 1.69
The dermatoscopic pattern of clear-cell acanthoma resembles psoriasis vulgaris. Dermatology (2001) 1.66
Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. Arch Dermatol (1996) 1.65
Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer (1997) 1.59
Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness. Br J Dermatol (2001) 1.56
Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol (1998) 1.54
Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol (1993) 1.52
Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol (1995) 1.50
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol (2007) 1.49
Dermoscopic classification of atypical melanocytic nevi (Clark nevi). Arch Dermatol (2001) 1.49
Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma. Results of a case control study in melanoma patients and nonmelanoma control subjects. J Am Acad Dermatol (1992) 1.47
Sporadic hypomelanosis of Ito with focal hypertrichosis in a 16-month-old girl. Dermatology (1996) 1.45
Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation. Am J Surg Pathol (1999) 1.45
Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol (1998) 1.43
Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol (2006) 1.43
[Microcirculation of cutaneous melanoma]. Hautarzt (1999) 1.40
[Elective lymph node dissection in primary malignant melanoma]. Hautarzt (1996) 1.39
[On the enzymatic organization of energy metabolism in normal guinea pig skin. I. Methodical data on the determination of enzyme activity in guinea pig skin]. Arch Klin Exp Dermatol (1965) 1.39
[Merkel cell tumor of the skin]. Dtsch Med Wochenschr (1997) 1.38
Oral hairy leukoplakia in 71 HIV-seropositive patients: clinical symptoms, relation to immunologic status, and prognostic significance. J Am Acad Dermatol (1996) 1.38
Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer (2010) 1.37
[On the enzymatic organization of energy metabolism in normal guinea pig skin. II. Determination of enzyme activity in energy metabolism]. Arch Klin Exp Dermatol (1965) 1.33
Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. Br J Dermatol (2000) 1.29
Melanocytes in nevi and melanomas synthesize basement membrane and basement membrane-like material. An immunohistochemical and electron microscopic study including immunoelectron microscopy. J Cutan Pathol (2000) 1.27
Interferons in dermatology. J Am Acad Dermatol (1989) 1.19
Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer (2012) 1.19
Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. Antimicrob Agents Chemother (2006) 1.18
Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res (1995) 1.18
Expression of interleukin 10 in human melanoma. Br J Cancer (1994) 1.15
Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer (1997) 1.12
Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? Br J Dermatol (2001) 1.12
Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma. Cancer (2001) 1.11
[On the enzymatic organization of the energy producing metabolism of normal guinea pig skin. 3. Activity determination of epidermal enzymes of the citric acid cycle and associated reactions]. Arch Klin Exp Dermatol (1966) 1.10
Molecular events in melanoma development and progression. Front Biosci (1998) 1.10
[On quantitative assessment of histochemical dehydrogenase demonstrations]. Histochemie (1965) 1.10
Agreement between self-assessment of melanocytic nevi by patients and dermatologic examination. Am J Epidemiol (2000) 1.10
Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle. Biophys J (2010) 1.08
Human afferent lymph from normal skin contains an increased number of mainly memory / effector CD4(+) T cells expressing activation, adhesion and co-stimulatory molecules. Eur J Immunol (2000) 1.06
Acute nongonococcal epididymitis. Aetiological and therapeutic aspects. Drugs (1987) 1.06
HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol (2001) 1.05
Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. Br J Dermatol (2004) 1.04
Extent and consequences of physician delay in the diagnosis of acral melanoma. Melanoma Res (1998) 1.04
Malignant chondroid syringoma: immunohistopathology. Am J Dermatopathol (1996) 1.03
Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy. Br J Dermatol (2005) 1.02
[Acanthosis]. Hautarzt (1969) 1.02
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer (2001) 1.02
Cutaneous nocardiosis caused by Nocardia brasiliensis after an insect bite. Dermatology (1999) 1.00
[Inhibition of enzymes of the carbohydrate metabolism by dithranol]. Arch Dermatol Forsch (1971) 1.00
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer (2003) 1.00
Primary malignant melanoma arising in a cystic necrotic ovarian teratoma. Eur J Obstet Gynecol Reprod Biol (2001) 1.00
Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol (2001) 0.97
Microstaging of squamous cell carcinomas. Am J Clin Pathol (1990) 0.97
Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol (2000) 0.96
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol (2006) 0.96
Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res (2000) 0.95
Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol (2001) 0.95
RNA isolation from human skin tissues for colorimetric differential display. J Biochem Biophys Methods (1998) 0.94
[Biochemical aspects of experimental acanthosis]. Arch Klin Exp Dermatol (1966) 0.94
Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Melanoma Res (1997) 0.94
Digital image analysis for diagnosis of cutaneous melanoma. Development of a highly effective computer algorithm based on analysis of 837 melanocytic lesions. Br J Dermatol (2004) 0.92
Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol (1991) 0.91